Citations

Clear

3042 citation(s) found for "Kumar, S".

Internalization of vasopressin analogs in kidney and smooth muscle cells: evidence for receptor-mediated endocytosis in cells with V2 or V1 receptors.
Lütz, W, Salisbury, J. L., Kumar, Rajiv , Sanders, Mathijs Arnoud , Kumar, Rajiv

Mayo Clinic

Proceedings of the National Academy of Sciences | May 31, 2006 | Volume: 87 | Issue: 17 | Pages: 6507-6511

10.1073/pnas.87.17.6507 | PMID 2144348 Get It

To determine whether receptor-mediated endocytosis occurs in vasopressin-responsive cells, we developed a model system using synthetic fluorescent-labeled vasopressin analogs and A10 (smooth muscle) and LLC-PK1 (kidney epithelial) cells in culture; these cell lines express V1 and V2 vasopressin cell surface receptor types, respectively. We used epifluorescence microscopy to examine the binding, internalization, and intracellular destination of [1-(2-mercapto)propionic acid,8-lysine-N6-carboxytetramethylrhodamine] vasopressin (R-MLVP) and [1-(2-mercapto)propionic acid,8-lysine-N6-carboxyfluorescein]vasopressin (F-MLVP) in these cells. The rhodamine-labeled fluorescent vasopressin analog, R-MLVP, initially bound in a diffuse manner at the cell surface of both A10 and LLC-PK1 cells and could be displaced by excess unlabeled [8-arginine]vasopressin. After incubation at 37 degrees C, bound ligand rapidly aggregated into small clusters or patches, which were internalized in a manner consistent with receptor-mediated endocytosis. Subsequent processing of internalized ligand-receptor complexes appeared to differ between A10 and LLC-PK1 cells. In the case of LLC-PK1 cells, ligand was delivered to a tightly focused lysosome compartment in the perinuclear region of the cell, and receptor molecules were replenished at the cell surface. The lysosomal location of ligand was supported by the quenching of fluorescence in the internalized vesicles when F-MLVP was used as a fluorescent tracer. In the case of A10 cells, ligand became localized to a vesicular compartment and reappearance of receptor at the cell surface was limited. Our data are consistent with the occurrence of receptor-mediated endocytosis of vasopressin in cells with V1 and V2 receptors.
Ontogeny of Phex/PHEX Protein Expression in Mouse Embryo and Subcellular Localization in Osteoblasts
Thompson, Daniah, Sabbagh, Yves , Tenenhouse, Harriet S., Roche, Patrick C. , Drezner, M. K., Salisbury, J. L., Grande, Joseph P. , Poeschla, Eric M. , Kumar, Rajiv , Kumar, Rajiv

Mayo Clinic

Journal of Bone and Mineral Research | April 27, 2006 | Volume: 17 | Issue: 2 | Pages: 311-320

10.1359/jbmr.2002.17.2.311 | PMID 11811562 Get It

Abstract PHEX, a phosphate-regulating gene with homologies to endopeptidases on the X chromosome, is mutated in X-linked hypophosphatemia (XLH) in humans and mice (Hyp). Although recent observations indicate that Phex protein is expressed primarily in bone and may play an important role in osteoblast function and bone mineralization, the pattern of the Phex protein expression in the developing skeleton and its subcellular localization in osteoblasts remain unknown. We examined the ontogeny of the Phex protein in the developing mouse embryo and its subcellular localization in osteoblasts using a specific antibody to the protein. Immunohistochemical staining of mouse embryos revealed expression of Phex in osteogenic precursors in developing vertebral bodies and developing long bones on day 16 postcoitum (pc) and thereafter. Calvaria from day 18 pc mice showed Phex epitopes in osteoblasts. No Phex immunoreactivity was detected in lung, heart, hepatocytes, kidney, intestine, skeletal muscle, or adipose tissue of mouse embryos. Interestingly, embryonic mouse skin showed moderate amounts of Phex immunostaining. In postnatal mice, Phex expression was observed in osteoblasts and osteocytes. Moderate expression of Phex was seen in odontoblasts and slight immunoreactivity was observed in ameloblasts. Confocal microscopy revealed the presence of immunoreactive PHEX protein in the Golgi apparatus and endoplasmic reticulum of osteoblasts from normal mice and in osteoblasts from Hyp mice transduced with a human PHEX viral expression vector. PHEX protein was not detected in untransduced Hyp osteoblasts. These data indicate that Phex protein is expressed in osteoblasts and osteocytes during the embryonic and postnatal periods and that within bone, Phex may be a unique marker for cells of the osteoblast/osteocyte lineage.
Parathyroid Hormone Regulates Transforming Growth Factor β1 and β2 Synthesis in Osteoblasts Via Divergent Signaling Pathways
Wu, Yanhong , Kumar, Rajiv , Kumar, Rajiv

Mayo Clinic

Journal of Bone and Mineral Research | April 27, 2006 | Volume: 15 | Issue: 5 | Pages: 879-884

10.1359/jbmr.2000.15.5.879 | PMID 10804017 Get It

Abstract Parathyroid hormone 1–34 [PTH(1–34)] was shown to increase transforming growth factor β1 (TGF-β1) and TGF-β2 concentrations in supernatants of cultured human osteoblasts and to increase TGF-β1 and TGF-β2 messenger RNA (mRNA) concentrations and gene transcription in these cells. Because PTH(1–34) activates both protein kinase C (PKC) and protein kinase A (PKA) pathways in osteoblasts, we investigated the role of each kinase pathway in activation of TGF-β3 isoforms. PTH(29–32), which activates the PKC pathway in rat osteoblasts, increased TGF-β1 but not TGF-β2 concentrations in supernatants of osteoblasts. Phorbol myristate acetate (PMA), a PKC agonist, increased TGF-β1 but not TGF-β2 concentrations. Specific PKC antagonists safingol and Gö6976 attenuated PTH(1–34)-mediated increases in TGF-β1 but not TGF-β2 synthesis. PTH(1–31), which increases PKA activity in several cell culture systems, increased TGF-β2 but not TGF-β1 concentrations in human osteoblast supernatants. Forskolin, a PKA agonist, increased TGF-β2 but not TGF-β1 concentrations in supernatants of human osteoblasts. The PKA antagonist H-89 blunted PTH(1–34)-mediated increases in TGF-β2 but not TGF-β1 synthesis. Our results are consistent with the concept that PTH increases TGF-β1 expression and secretion by pathways that involve the PKC pathway, whereas it increases TGF-β2 expression and secretion via the PKA pathway. (J Bone Miner Res 2000;15:879–884)
Long-Term Effects of Calcium Supplementation on Serum Parathyroid Hormone Level, Bone Turnover, and Bone Loss in Elderly Women
Riggs, B. Lawrence, O’Fallon, W. Michael, Muhs, Joan M., O’Connor, Michael K. , Kumar, Rajiv , Melton, L. Joseph, Kumar, Rajiv

Mayo Clinic

Journal of Bone and Mineral Research | April 27, 2006 | Volume: 13 | Issue: 2 | Pages: 168-174

10.1359/jbmr.1998.13.2.168 | PMID 9495509 Get It

Abstract We report a 4-year randomized, double-blind, placebo-controlled clinical trial in 236 normal postmenopausal women (mean age ± SE, 66.3 ± 0.2 years) who were randomized to a calcium (1600 mg/day as the citrate) or placebo group. The women were seen every 6 months; 177 completed the trial. Net percentage changes in each group are given relative to baseline. The differences in net percentage changes (calcium group minus placebo group) in medians were: for lumbar spine bone density, 2.0% (p < 0.001) at year 1 and 0.3% (not significant) at year 4; for proximal femur bone density, 1.3% (p = 0.003) at year 1 and 1.3% (p = 0.015) at year 4; and for total body bone mineral, 0.4% (p = 0.002) at year 1 and 0.9% (p = 0.017) at year 4. Similar differences at year 4 were: −18.9% (p = 0.002) for parathyroid hormone (PTH), −11.9% (p = 0.026) for serum osteocalcin, and −32.2% (p = 0.003) for urine free pyridinoline. We conclude that long-term administration of calcium supplements to elderly women partially reverses age-related increases in serum PTH level and bone resorption and decreases bone loss. However, the effects on bone loss were weaker than those reported for estrogen, bisphosphonates, or calcitonin therapy, indicating that calcium supplements alone cannot substitute for these in treating established osteoporosis. Nonetheless, because of their safety, high tolerance, and low expense, calcium supplements may be a useful preventive measure for elderly postmenopausal women whose bone mineral density values are normal for their age.
Tumors Associated With Oncogenic Osteomalacia Express Genes Important in Bone and Mineral Metabolism
Finnegan, Richard B., Vassiliadis, John, Cook, Brian P., Barberio, Dana , Estes, Scott , Manavalan, Partha, Petroziello, Joseph M., Madden, Stephen L., Cho, Justin Y., Kumar, Rajiv , Levine, Michael A. , Schiavi, Susan C., Beur, Suzanne M. Jan de , Madden, Stephen L., Kumar, Rajiv , Levine, M A

Mayo Clinic

Journal of Bone and Mineral Research | April 26, 2006 | Volume: 17 | Issue: 6 | Pages: 1102-1110

10.1359/jbmr.2002.17.6.1102 | PMID 12054166 Get It

Abstract Oncogenic osteomalacia (OOM) is associated with primitive mesenchymal tumors that secrete phosphaturic factors resulting in low serum concentrations of phosphate and calcitriol, phosphaturia, and defective bone mineralization. To identify overexpressed genes in these tumors, we compared gene expression profiles of tumors resected from patients with OOM and histologically similar control tumors using serial analysis of gene expression (SAGE). Three hundred and sixty-four genes were expressed at least twofold greater in OOM tumors compared with control tumors. A subset of 67 highly expressed genes underwent validation with an extended set of OOM and control tumors using array analysis or reverse-transcription polymerase chain reaction (RT-PCR). Ten of these validated genes were consistently overexpressed in all OOM tumors relative to control tumors. Strikingly, genes with roles in bone matrix formation, mineral ion transport, and bone mineralization were highly expressed in the OOM tumors.
Superficial siderosis
Kumar, Neeraj , Cohen‐Gadol, Aaron , Wright, R. A., Miller, Gary M. , Piepgras, D. G., Ahlskog, J. E.

Mayo Clinic

Neurology | April 24, 2006 | Volume: 66 | Issue: 8 | Pages: 1144-1152

10.1212/01.wnl.0000208510.76323.5b | PMID 16636229 Get It

Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: Conference Summary Statement
Come, Steven E. , Buzdar, Aman U. , Arteaga, Carlos L. , Brown, Myles , Kumar, Rakesh , Johnston, Stephen, Paik, Soonmyung , Hart, Carol S. , Ingle, James N. , Dowsett, Mitch , Hilsenbeck, Susan Galloway , Lee, Adrian V. , Pritchard, Kathleen I. , Winer, Eric P. , Brown, Myles

Mayo Clinic

Clinical Cancer Research | March 21, 2006 | Volume: 12 | Issue: 3 | Pages: 997s-1000s

10.1158/1078-0432.ccr-05-2268 | PMID 16467115 Get It

Melarsoprol-associated multifocal inflammatory CNS illness in African trypanosomiasis
Orenstein, Robert , Uslan, Daniel Z. , Berbari, Elie F. , Klein, Christopher J. , Windebank, Anthony J. , Kumar, Naveen , Klein, Christopher J

Mayo Clinic

Neurology | March 16, 2006 | Volume: 66 | Issue: 7 | Pages: 1120-1121

10.1212/01.wnl.0000202519.59577.4c | PMID 16540605 Get It

Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
Dispenzieri, Angela , Lacy, Martha Q. , Katzmann, Jerry A., Rajkumar, S. Vincent , Abraham, Roshini S. , Hayman, Suzanne R. , Kumar, Shaji , Clark, Raynell, Kyle, Robert A. , Litzow, Mark R. , Inwards, David J. , Ansell, Stephen M. , Micallef, Ivana M., Porrata, Luis F. , Elliott, Michelle A. , Johnston, Patrick B. , Greipp, Philip R., Zeldenrust, Steven R., Gastineau, Dennis A., Witzig, Thomas E. , Russell, Stephen J. , Gertz, Morie A. , Rajkumar, S Vincent , Dispenzieri, Angela

Mayo Clinic

Blood | January 6, 2006 | Volume: 107 | Issue: 8 | Pages: 3378-3383

10.1182/blood-2005-07-2922 | PMID 16397135 Get It

AbstractThe immunoglobulin free light chain (FLC) is the precursor protein of amyloid in primary systemic amyloidosis (AL). Historically, the ability to monitor the amyloid protein precursor protein has been crude. We evaluated the utility of the FLC assay in a retrospective analysis of patients with AL undergoing peripheral blood stem cell transplantation (PBSCT). Ninety-three such patients had serial FLC measurements performed. The prognostic effects of the initial concentration and the extent of reduction of monoclonal FLC on survival were studied. There was a significantly higher risk of death in patients with higher baseline FLC (hazard ratio 2.6, P < .04). Baseline FLC correlated with serum cardiac troponin levels, and higher FLC levels were associated with more organs involved by amyloid, suggesting that high FLC levels may be associated with more advanced disease. The percent FLC reduction did not predict for survival, but the absolute level of FLC achieved after therapy did. Normalization of FLC level after PBSCT predicted for both organ response and complete hematologic response. Achievement of FLC response was a better predictor of survival than achievement of complete hematologic response or normalization of the FLC ratio. FLC measurements both before and after PBSCT are important predictors of patient outcome.
Bortezomib Mediates Antiangiogenesis in Multiple Myeloma via Direct and Indirect Effects on Endothelial Cells
Roccaro, Aldo M. , Hideshima, Teru , Kumar, Shaji , Ishitsuka, Kenji , Yasui, Hiroshi , Shiraishi, Norihiko, Nico, Beatrice, Dammacco, Franco , Richardson, Paul G. , Raje, Noopur , Ribatti, Doménico , Vacca, Angelo , Richardson, Paul Gerard Guy , Anderson, Kenneth C. , Roccaro, Aldo M

Mayo Clinic

Cancer Research | January 5, 2006 | Volume: 66 | Issue: 1 | Pages: 184-191

10.1158/0008-5472.can-05-1195 | PMID 16397231 Get It

AbstractBone marrow angiogenesis plays an important role in the pathogenesis and progression in multiple myeloma. Recent studies have shown that proteasome inhibitor bortezomib (Velcade, formerly PS-341) can overcome conventional drug resistance in vitro and in vivo; however, its antiangiogenic activity in the bone marrow milieu has not yet been defined.In the present study, we examined the effects of bortezomib on the angiogenic phenotype of multiple myeloma patient–derived endothelial cells (MMEC). At clinically achievable concentrations, bortezomib inhibited the proliferation of MMECs and human umbilical vein endothelial cells in a dose-dependent and time-dependent manner. In functional assays of angiogenesis, including chemotaxis, adhesion to fibronectin, capillary formation on Matrigel, and chick embryo chorioallantoic membrane assay, bortezomib induced a dose-dependent inhibition of angiogenesis. Importantly, binding of MM.1S cells to MMECs triggered multiple myeloma cell proliferation, which was also abrogated by bortezomib in a dose-dependent fashion. Bortezomib triggered a dose-dependent inhibition of vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) secretion by the MMECs, and reverse transcriptase-PCR confirmed drug-related down-regulation of VEGF, IL-6, insulin-like growth factor-I, Angiopoietin 1 (Ang1), and Ang2 transcription. These data, therefore, delineate the mechanisms of the antiangiogenic effects of bortezomib on multiple myeloma cells in the bone marrow milieu. (Cancer Res 2006; 66(1): 184-91)